Medicalook
Medicalook

Dornase

http://www.medicalook.com
Dornase alfa

Dornase review





The Dornase alfa drug is a drug solution highly purified from recombinant human deoxyribonuclease I (rhDNase), an enzyme found out to selectively cleave DNA. This is a protein therapeutic agent produced in ovary cells from Chinese hamsters. A nutrient medium that contains an antibiotic gentamicin ferments the engineered cells. This is then further purified by tangential flow filtration and column chromatography. This will become a purified glucoprotein, containing around 260 amino acids, with its primary amino acid sequence identical to that of a human enzyme.

The basic action of dornase alfa is to hydrolyze the mucus of cystic fibrosis patients and then reduce its viscosity in the lungs, in order to promote improved clearance of secretions. Prior to the development of dornase alfa, bovine DNase I was its predecessor, however, it was limited because of the antigenic response of the patients to cow protein.

Dornase alfa is administered daily as Pulmozyne Inhalation Solution along with other therapies for the management of patients with cystic fibrosis in order to improve their pulmonary functions. It has been shown that dorsane alfa reduces the risk of respiratory tract infections that require parenteral antibiotics.

Pulmozyne is administered by inhaling an aerosol mist through a nebulizer system. A single use ampoule of dorsane alfa delivers 2.5mL of the solution to the nebulizer. Aqueous solutions contain 1.0mg/mL f dorsane alfa, 0.15mg/mL of calcium chloride dehydrate and 8.77mg/mL of sodium chloride.

No known side effects of dorasane alfa have been reported for cystic fibrosis patients, apart from the progress of the condition. To date, no reports of anaphylaxis were reported upon administration of Pulmozyne. Skin rashes have been observed in some patients.

Dorsane Alfa has been reported to be safely administered with standard cystic fibrosis therapies which may include oral, inhaled antibiotics, bronchodilators, vitamins, enzyme supplements, corticosteroids whether inhaled or oral, and analgesics.

Clinical tests have reported that prolonged use of dorsane alfa yielded no increase in development of benign or malignant tumors. There has been no evidence as well of chromosomal damage brought about by usage of dorsane alfa. Studies have also reported that dorsane alfa does not affect the reproductive performance of both male and females.

Pregnant women should only use Dorsane Alfa if it is clearly needed. No supporting evidence shows if dorsane alfa is excreted in human breast milk. Caution should always be exercised when administering drugs to a nursing mother, including dorsane alfa. The benefits that dornase alfa may bring must be weighed against the risk it may bring to the nursing infant.

The administration of dorsane alfa to both the young (pediatric) and older patients (geriatric) must be given caution. The potential benefits to the user must be considered as well as the harm and risk administering dorsane alfa may bring about. As cystic fibrosis is primarily a disease of pediatrics and young adults, little is known of the effects it would have on patients 65 years or older.

• Molecular formula of dornase alfa is C1321H1999N339O396S9
• Molecular weight is 29253.9 g/mol

  Your Dornase review